Functional Profiling Could Map Breast Cancer Vulnerabilities
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The future of breast cancer therapies may lie in targeting the functional commonalities among cancer cells across tumor types rather than the gene mutations that set them apart – or, even better, overlaying the two data sets to create an integrated approach, say cancer geneticists from the Institute for Cancer Research in London.